Scotiabank Remains a Buy on Aura Biosciences Inc (AURA)

Scotiabank analyst George Farmer reiterated a Buy rating on Aura Biosciences Inc (AURA – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $7.54.

Farmer covers the Healthcare sector, focusing on stocks such as Legend Biotech, Tempest Therapeutics, and SAGE Therapeutics. According to TipRanks, Farmer has an average return of 16.0% and a 55.13% success rate on recommended stocks.

Aura Biosciences Inc has an analyst consensus of Strong Buy, with a price target consensus of $19.75, representing a 161.94% upside. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $21.00 price target.

Based on Aura Biosciences Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.13 million. In comparison, last year the company had a GAAP net loss of $16.56 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aura Biosciences Inc (AURA) Company Description:

Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.